Since PARP-1 activation is critical for sensing and recovery of DNA damage [56], systemic or long-term treatment with PARP-1 inhibitors may cause serious side effects, like teratogenicity and anaemia [36, 57].Thus, spatiotemporal or conditional inhibition would be preferred in clinical interests. The gene discussed is PARP1; the disease is anemia (phenotype).